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Abstract
Clostridium difficile infection (CDI) has been primarily treated with metronidazole or vancomycin. High recurrence rates, the
emergence of epidemic PCR ribotypes (RTs) and the introduction of fidaxomicin in Europe in 2011 necessitate surveillance of
antimicrobial resistance and CDI epidemiology. The ClosER study monitored antimicrobial susceptibility and geographical distri-
bution of C. difficile RTs pre- and post-fidaxomicin introduction. From 2011 to 2016, 28 European countries submitted isolates or
faecal samples for determination of PCR ribotype, toxin status and minimal inhibitory concentrations (MICs) of metronidazole,
vancomycin, rifampicin, fidaxomicin, moxifloxacin, clindamycin, imipenem, chloramphenicol and tigecycline. RT diversity scores
for each country were calculated and mean MIC results used to generate cumulative resistant scores (CRSs) for each isolate and
country. From 40 sites, 3499 isolates were analysed, of which 95% (3338/3499) were toxin positive. The most common of the 264
RTs isolated was RT027 (mean prevalence 11.4%); however, RT prevalence varied greatly between countries and between years.
The fidaxomicin geometric mean MIC for years 1–5 was 0.04 mg/L; only one fidaxomicin-resistant isolate (RT344) was submitted
(MIC ≥ 4 mg/L). Metronidazole and vancomycin geometric mean MICs were 0.46 mg/L and 0.70 mg/L, respectively. Of prevalent
RTs, RT027, RT017 and RT012 demonstrated resistance or reduced susceptibility to multiple antimicrobials. RT diversity was
inversely correlated with mean CRS for individual countries (Pearson coefficient r = − 0.57). Overall, C. difficile RT prevalence
remained stable in 2011–2016. Fidaxomicin susceptibility, including in RT027, wasmaintained post-introduction. Reduced ribotype
diversity in individual countries was associated with increased antimicrobial resistance.
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Introduction
Clostridium difficile infection (CDI) represents a major
healthcare burden in the developed world [18].
Metronidazole and vancomycin have been the mainstays
of CDI treatment in recent decades [24]; however, high
recurrence rates and reports of reduced susceptibility to
metronidazole among epidemic C. difficile PCR
ribotypes (RTs) have highlighted the need for new
agents [1, 24]. Fidaxomicin is a macrocyclic antibiotic
with low MICs against C. difficile, approved by the
EMA in 2011 for the treatment of CDI in adults [7].
In two phase 3, double-blind, randomized, parallel-
group trials, it demonstrated non-inferiority in initial
cure of CDI and lower rates of recurrence, compared
with oral vancomycin [5, 15]. Fidaxomicin is also
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associated with greater preservation of the intestinal mi-
crobiota compared with vancomycin [14].
The aims of the 5-year ClosER study (2011–2016)
were to identify and monitor the longitudinal antimicrobi-
al susceptibility of C. difficile clinical isolates, including
those previously implicated in selection pressure, to estab-
lish a comprehensive susceptibility database baseline for
ongoing surveillance and to provide data on the geograph-
ical distribution of clinical C. difficile strain types across
Europe.
Methods
ClosER was a Pan-European, multicentre, in vitro surveil-
lance study, planned to provide data for 1 year prior to the
introduction of fidaxomicin (July 2011–June 2012) and
2 years post-introduction (2012–2014). It was subsequent-
ly extended for a further 2 years (2014–2016).
Participating centres were mostly national or regional
C. difficile referral laboratories selected using the
European Study Group on Clostr idium dif f ic i le
(ESGCD) network and with ESGCD approval. The num-
ber of sites approached per country was based on popu-
lation (1 site per 15 million population) or reported inci-
dence of CDI (≥ 2 sites for countries with > 20 cases per
10,000 patient days per hospital). Fifty-one sites from 28
European countries were asked to participate. Criteria for
site inclusion were active sampling and testing for CDI,
sufficient numbers of clinical CDI cases to reach a target
of 25 de-duplicated cases during the 6-month collection
period and a willingness to submit the required number of
samples over the 3 years. The 40 sites that contributed
samples during years 1–3 were contacted to request their
participation in years 4 and 5 of the study. Of these, 28
sites agreed to participate in the extended study, three
sites formally ended their participation after year 3, and
nine sites were unresponsive.
Isolates or faecal samples were submitted to a central
laboratory (Leeds, UK) for PCR ribotyping, determina-
tion of toxin status and assessment of susceptibility to
metronidazole, vancomycin, rifampicin, fidaxomicin,
moxifloxacin, clindamycin, imipenem, chloramphenicol
and tigecycline, using methods described previously [9,
10] (Online Resource 1). Participating sites were asked
to provide the following demographic data to accompa-
ny each sample: age, gender, history of CDI in the
previous 6 months, healthcare or community CDI epi-
sode, and antimicrobial administration 1 month prior to
the episode.
RT diversity and Cumulative Resistance Scores were




Across the 5 years of the study, a total of 3656 faecal samples
or C. difficile isolates were submitted, yielding 3499 isolates
of which 95% (n = 3338) were toxin positive (Table 1). Only
six countries participated in all years of the study:
Czech Republic, France, Germany, Ireland, Spain and the
UK. Preliminary data for year 1 and complete data for years
1–3 have been published previously [9, 10].
In any given year, less than one-quarter of sites submit-
ted complete demographic datasets (Table 1). Prior occur-
rence of CDI was indicated for 418 (19.4%) of the 2154
samples for which information was available. There was a
degree of variation between RTs with regard to prior oc-
currence of CDI (Table 2); however, these data should be
interpreted with caution due to the lack of information for
the majority of samples. Complete antimicrobial treatment
data was received from < 30% of sites in each year of the
study; analysis was, therefore, not performed on these data
due to the potential for bias in the use of incomplete
information.
PCR ribotype prevalence and distribution
Across years 1, 2, 3, 4 and 5 of the study, there were 114, 144,
120, 107 and 66 respective known PCR RTs isolated, making
a total of 264 distinct RTs. The most commonly isolated RTs
(prevalence ≥ 1%) in all years are listed in Table 3. RT prev-
alence and diversity scores variedmarkedly between countries
and between each year of the study (Fig. 1a–e).
Ribotype prevalence and distribution
RT prevalence results for years 1–3 have been described in
detail previously [9, 10]. RT027 was the most commonly iso-
lated RT at a mean prevalence of 11.4% across years 1–5
(Table 3). RT027 was highly prevalent in Poland for all years
that submissions were received (years 1–3) and in Hungary in
year 1. In Cyprus, its prevalence increased each year from
28% in year 1 to 89% in year 4 (no submissions were received
from Cyprus in year 5). For countries that provided samples in
all 5 years of the study, although fluctuations were apparent,
the most prevalent RTs remained broadly consistent between
2011 and 2016 (Online Resource 2).
Ribotype diversity
RT diversity varied between countries and between years
(Fig. 2). The highest overall RT diversity was seen in
Belgium (RT diversity scores 0.96, 0.84 and 0.92 for years
1, 2 and 4, respectively). Although high scores were also
170 Eur J Clin Microbiol Infect Dis (2020) 39:169–177
found for Bulgaria, it was omitted from this analysis due to the
very low sample numbers submitted each year.
Antimicrobial susceptibility
Fidaxomicin
Almost all isolates from years 1 to 5 were susceptible to
≤ 1 mg/L fidaxomicin (Online Resource 3; Online Resource
4; Online Resource 5), with an overall geometric mean MIC
of 0.04 mg/L across all years of the study. A single
fidaxomicin-resistant isolate (MIC ≥ 4 mg/L) was obtained
in France in year 5 and found to be RT344. All other RT344
isolates (n = 5) were susceptible to fidaxomicin (MIC 0.004–
0.5 mg/L) (Online Resource 6).
Fidaxomicin MICs were highest for RT198 at 0.04–
0.10 mg/L over years 1–4. No RT198 was isolated in year 5.
Fidaxomicin MICs for RT027 isolates varied between 0.02
and 0.08 mg/L over years 1–5. RT017, which was associated
with the most isolates with multiple antimicrobial resistance in
years 1, 2, 3 and 5 (see below), had MICs of 0.01–0.05 mg/L
and showed no sign of reduced susceptibility to fidaxomicin.
Similarly, RT012 had the most multiple antimicrobial-
resistant isolates in year 4 but showed no sign of reduced
susceptibility to fidaxomicin (MIC 0.03–0.05 mg/L). There
was also no evidence of reduced susceptibility among newly
emergent RTs with multiple antimicrobial resistance, such as
















1 39 7/39 (17.9) 14/39 (35.9) 3/39 (7.7) 978 944 897/944 (95.0)
2 40 6/40 (15.0) 16/40 (40.0) 7/40 (17.5) 1003 948 910/948 (96.0)
3 33 7/33 (21.2) 19/33 (57.6) 9/33 (27.3) 846 808 770/808 (95.3)
4 23 2/23 (8.7) 10/23 (43.5) 1/23 (4.3) 575 560 529/560 (94.5)
5 7 1/7 (14.3) 3/7 (42.9) 0/7 (0) 254 239 232/239 (97.1)
Total – – – – 3656 3499 3338/3499 (95.4)
Fifty-one sites in total were initially contacted. Submissions include both isolates and faecal samples
Table 2 Proportions of the most prevalent ribotypes (n > 70) isolated over years 1–5 of the ClosER study, by gender, age group, source and previous
CDI history
Ribotype Gender, % (N = 2577) Median age
(years)
Age in years, % (N = 2460) Source, % (N = 2269) Prior CDI,
% (N = 2154)





027 46.56 53.44 77 0.00 0.43 3.85 14.96 58.12 22.65 20.4 72.9 65.1 26.0
014 41.18 58.82 71 1.44 2.40 9.62 20.67 44.71 21.15 23.6 67.0 67.9 23.9
001 47.00 53.00 73 0.97 1.94 9.71 20.87 53.40 13.11 9.9 79.7 79.3 12.4
078 49.69 50.31 73 0.42 6.28 14.64 33.89 14.64 30.13 24.3 70.3 73.1 18.6
002 46.73 53.27 68 1.77 2.65 15.04 20.35 50.44 9.73 24.7 66.3 75.0 14.8
020 49.59 50.41 69 3.31 7.44 14.05 16.53 43.80 14.88 17.5 76.3 70.3 22.5
005 46.75 43.25 72 0.87 2.61 24.35 32.17 30.43 9.57 22.1 75.0 70.6 17.6
126 57.45 42.55 73 1.27 1.27 8.86 35.44 31.65 21.52 14.1 83.5 73.3 23.3
015 46.75 44.87 70 9.20 5.75 16.09 20.69 28.74 19.54 31.9 62.3 84.5 12.7
All isolates 46.91 53.08 71 1.42 9.75 7.44 15.01 30.87 35.52 20.4 72.9 73.8 19.5
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RT356 and RT018, which are closely related RTs with MICs
of 0.03–0.05 mg/L over the years that these were isolated.
Metronidazole and vancomycin
Metronidazole and vancomycin were highly active with very
little variation in sensitive, intermediate and resistant isolates
over years 1–4. Geometric mean MICs for years 1–5 were
0.46 mg/L and 0.70 mg/L for metronidazole and vancomycin,
respectively. Reduced metronidazole susceptibility was mainly
observed in RT027 and RT198 (Online Resource 4). Although
vancomycin MICs above the geometric mean were observed in
RT018 (years 1 and 4) and RT356 (years 1 and 3) from Italy,
geometric mean vancomycin MICs for these RTs were similar
to those for all isolates in other years (Online Resource 4).
Geometric mean vancomycin MICs also increased in RT126
from 0.66 mg/L in year 1 to 1.00 mg/L in Year 5.
Rifampicin
Numbers of isolates resistant to rifampicin decreased slightly
over the course of the study from 13.5% in year 1 to 10.2–
11.8% in years 4–5 (Online Resource 3). The more prevalent
RTs 027, 198, 018, 356, 017 and 176 had notably high propor-
tions of rifampicin resistance.
Moxifloxacin and clindamycin
Resistance to both moxifloxacin and clindamycin was com-
mon and evident in all participating countries but varied be-
tween years and between countries (Online Resource 3;
Online Resource 4). For example, clindamycin resistance in
the Czech Republic fluctuated between 24 and 63% during the
study.
Imipenem, chloramphenicol and tigecycline
The majority of isolates in all years were susceptible to
imipenem, and the highest geometric mean MICs were
found for RT176 (10.37 mg/L, year 5) and RT017
(10.56 mg/L, year 3) (Online Resource 4). The majority
of isolates were susceptible to chloramphenicol, but
higher geometric mean MICs were observed in RT001
and RT017. Reduced susceptibility to tigecycline (MIC
> 0.25 mg/L) was also scarce; however, geometric mean
MICs were marginally elevated in RT012.
Multiple antimicrobial resistance
Of the prevalent RTs, RT027 consistently demonstrated
resistance or reduced susceptibility to metronidazole, ri-
fampicin, moxifloxacin and imipenem, while RT001 had
consistently elevated geometric mean moxifloxacin,
Table 3 Percentage prevalence (> 1%) of C. difficile PCR ribotypes in years 1–5 of the ClosER study













027 115 12.2 027 112 11.8 027 101 12.6 027 65 11.3 014 30 11.8 027 404 11.4
001 86 9.1 014 89 9.4 014 85 10.6 001 43 7.5 106 21 8.3 014 321 9.1
078 76 8.1 001 77 8.1 001 63 7.8 014 43 7.5 002 20 7.9 001 283 8.0
014 74 7.8 002 53 5.6 020 44 5.5 078 39 6.8 078 20 7.9 078 231 6.5
020 38 4.0 078 53 5.6 078 43 5.4 002 32 5.6 001 13 5.1 002 175 4.9
126 35 3.7 020 49 5.2 126 41 5.1 020 24 4.2 020 13 5.1 020 168 4.7
002 34 3.6 005 31 3.3 002 35 4.4 005 22 3.8 027 11 4.3 005 122 3.4
015 32 3.4 015 31 3.3 005 31 3.9 015 21 3.7 176 8 3.1 126 121 3.4
005 31 3.3 126 31 3.3 015 22 2.7 012 15 2.6 005 7 2.8 015 112 3.2
106 24 2.5 018 28 3.0 046 19 2.4 039 11 1.9 015 6 2.4 106 85 2.4
023 23 2.4 023 20 2.1 106 18 2.2 003 10 1.7 017 6 2.4 018 69 1.9
018 21 2.2 017 18 1.9 017 15 1.9 070 9 1.6 126 6 2.4 017 62 1.7
356 21 2.2 046 17 1.8 176 13 1.6 106 9 1.6 023 5 2.0 023 61 1.7
012 19 2.0 012 14 1.5 018 12 1.5 176 9 1.6 050 5 2.0 012 60 1.7
011 16 1.7 198 14 1.5 003 11 1.4 018 8 1.4 081 5 2.0 046 58 1.6
017 16 1.7 106 13 1.4 010 11 1.4 126 8 1.4 070 4 1.6 176 47 1.3
046 15 1.6 056 11 1.2 081 11 1.4 017 7 1.2 012 3 1.2 011 40 1.1
087 15 1.6 029 10 1.1 011 10 1.2 043 7 1.2 013 3 1.2 081 39 1.1
056 11 1.2 039 10 1.1 023 10 1.2 010 6 1.0 056 3 1.2 003 35 1.0
Other 241 25.5 081 10 1.1 070 10 1.2 013 6 1.0 154 3 1.2 070 35 1.0
Other 257 27.1 012 9 1.1 054 6 1.0 Other 58 22.8 198 35 1.0
198 8 1.0 198 6 1.0 Other 960 27.3
Other 180 22.4 Other 160 27.9
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clindamycin and chloramphenicol MICs. Other prevalent
RTs showed reduced susceptibility to multiple antimicro-
bials. Some RT017 isolates had elevated geometric mean
rifampicin, moxifloxacin and clindamycin MICs in years
1 and 4 and elevated imipenem and chloramphenicol
MICs in years 2, 3 and 5. RT017 in years 1–3 and year
5, plus RT012 in year 4, demonstrated resistance to the
broadest range of antimicrobials tested.
Antimicrobial susceptibility by country
Of the countries that submitted data for all 5 years of the study,
Ireland and the UK showed generally reducing CRS over the
first 4 years of the study, increasing slightly in year 5 (year 1:
Ireland 2.26, UK 2.16; year 4: Ireland 0.87, UK 0.49; year 5:
Ireland 1.22, UK 1.25) (Online Resource 7). When all coun-
tries included in the study were analysed, there was a signif-
icant inverse correlation between RT diversity and mean CRS
for individual countries (Pearson coefficient r = − 0.57; corre-
lation significance p = 0.004) (Online Resource 8). This indi-
cated lower antimicrobial resistance levels in countries with a
greater C. difficile RT diversity.
Discussion
To date, this is the largest Pan-European study of C. difficile
RT prevalence and antimicrobial resistance. Almost 3500
Fig. 1 Percentage prevalence by country of C. difficile PCR ribotypes in a year 1, b year 2, c year 3, d year 4 and e year 5 of the ClosER study. aNo
submissions received from this country. Other = all other ribotypes with prevalence < 1%
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isolates were received, yielding 264 distinct RTs. Over the first
4 years of the study, the prevalence of the 10 most common
RTs remained stable and the changes observed in year 5
should be interpreted with caution due to a substantially re-
duced number of submissions and participating countries. The
most prevalent RTs found in our study correspond closely to
those previously reported in 2011 [3] and 2016 [6], indicating
overall stability in RT prevalence over time. Some fluctuation
in relative RT prevalence between years and between coun-
tries was observed, as expected due to endemic and epidemic
spread of C. difficile [8]. Previously described epidemic or
highly prevalent RTs, such as 014, 027, 001 and 078,
remained highly prevalent in this study. RT005, RT087 and
RT356 were more prevalent in year 1 than previously ob-
served [3], but of these, only RT005 remained highly preva-
lent throughout the study.
Fidaxomicin MICs remained consistently low throughout
the 5 years of the study, and there was no evidence of a reduc-
tion in susceptibility following its introduction in 2011. This is
consistent with an earlier antimicrobial susceptibility survey
of isolates from two phase III studies of 1164 patients that
reported fidaxomicin MIC90s of 0.25 mg/L [11]. The same
survey identified a single strain of C. difficile from a patient
with recurrence with a fidaxomicin MIC of 16 mg/L; howev-
er, the relatedness of the pre- and post-treatment strains was
not determined [11], and the association of resistance with
drug exposure cannot be made definit ively [21].
Schwanbeck et al. described fidaxomicin resistance (MIC
> 64 mg/L), associated with a V1143D mutation in rpoB, in
a single clinical C. difficile isolate of 50 isolates tested [19];
however, the fitness burden imposed by the mutation was
higher when generated in vitro [13, 19] than observed in the
clinical isolate [19]. In the light of high fidaxomicin gut con-
centrations, the significance of this is unclear but highlights
the need for further monitoring. We report a single
fidaxomicin-resistant isolate of RT344 (MIC ≥ 4 mg/L), iso-
lated in year 5 of the study; this isolate was also resistant to
moxifloxacin, clindamycin and imipenem, but sensitive to all
other antimicrobials tested. All other RT344 isolates submit-
ted were susceptible to fidaxomicin.
RT027, the most prevalent RT in the ClosER study, has
previously been associated with multiple antimicrobial re-
sistance [17] and reduced susceptibility to fidaxomicin
compared with other PCR ribotypes (MIC90s 0.5 mg/L
versus ≤ 0.25 mg/L, respectively) [11]. However, no such
association was found in the ClosER study. The geometric
mean fidaxomicin MIC for the RT027 isolates submitted
to this study (0.04–0.08 mg/L) was below the susceptibil-
ity breakpoint. Likewise, RT017, 012, 018 and 356
showed resistance to multiple antimicrobials in this study
but were not associated with higher fidaxomicin MICs.
Moreover, the clinical significance of RT-specific varia-
tions in fidaxomicin susceptibility is questionable, partic-
ularly given the high concentrations of fidaxomicin
(> 1000 μg/g) attained in the gut [20].
While susceptibility to fidaxomicin remained stable over
years 1–5, susceptibility to metronidazole and vancomycin
increased. This could be attributed to a reduction in metroni-
dazole and vancomycin use and/or greater strain diversity. The
present study confirmed previously reported associations be-
tween prevalent RTs, such as RT027 and RT001, and resis-
tance to moxifloxacin, clindamycin and chloramphenicol [2,
16, 22]. However, there were examples of these RTs from
many countries showing almost full susceptibility to all
agents. Imipenem resistance is not well-documented for
C. difficile, but we found evidence of both intermediate and
full resistance in all years.
Fluctuations in antimicrobial susceptibility between coun-
tries and between years are reflective of the varying preva-
lence of RTs. Multiple antimicrobial resistance was most ev-
ident in certain epidemic RTs, such as RT027 and 001, but was
also notable in RT017, RT012, emerging RT198 (exclusive to
Hungary) and RT356 (exclusive to Italy). We found a consis-
tent inverse correlation between RT diversity and mean CRS
Fig. 2 Ribotype diversity by
country during years 1–5 of the
ClosER study
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for a given country, possibly due to the introduction of man-
datory reporting programmes with a subsequent increase in
awareness, antimicrobial stewardship and infection control
interventions reducing rates of endemic RTs.
The selection criteria for submissions stipulated 25 de-
duplicated toxin-positive faecal samples or C. difficile iso-
lates, with no further requirements. There may, therefore,
be selection bias in the samples submitted from any loca-
tion. Participating centres were mainly national or region-
al C. difficile reference facilities and, therefore, some sub-
missions likely included outbreak strains, possibly
influencing the data. The majority of submissions were
isolates rather than faecal samples. The recovery rate
was generally poorer from faecal samples (mean 86%;
median 84%) than from isolates (mean 97%; median
100%). In years 1 and 2, three sites submitted faecal sam-
ples, with recovery rates between 64 and 100%. In years 3
and 4, two of these sites submitted isolates: for one of
these sites, recovery rates increased to 100% in both
years, while for the other site, recovery rates increased
to 84% and 92% in years 3 and 4, respectively.
We advised sites on how to prepare isolates as spores for
transport but did not obtain information onwhether this advice
had been followed. We experienced consistently poor
C. difficile recovery from isolate submissions by one site dur-
ing all 3 years of their participation (76%, 40% and 52%).
Another site had a recovery rate of 100% in year 1, but this
rate dropped to 88% and 82% for years 2 and 3, respectively,
after changing to different transport conditions. It was notable
that all of these were not submitted as advised in transport
media, and it is possible that this contributed to the poor re-
covery rates. However, these sites were not the only partici-
pating locations from their country (1 of 3 and 1 of 4, respec-
tively) and, therefore, the effect of low recovery rates was
lessened somewhat. Despite these site-specific limitations,
overall recovery rates were > 96% for 90%, 83%, 85% and
91% of sites in years 1, 2, 3 and 4, respectively.
There was a substantial decrease in the responsiveness of
sites, and consequently the number of submissions, during
years 4 and 5. Possible reasons for a lack of response included
site staff resourcing issues, the extended duration of the study
and the loss or retirement of named site contacts or national
coordinators. Although sample transport was provided, couri-
er transport was problematic in some countries and there was
no financial incentive for sites to submit samples. In year 5,
only the Czech Republic, France, Germany, Ireland, Spain and
the UK submitted isolates. From the UK, only one site sub-
mitted samples in year 5, while all four sites consistently sub-
mitted samples in years 1–4. Countries with high RT027 prev-
alence were, therefore, not represented in year 5, skewing the
data. Accompanying patient data, particularly information on
antimicrobial treatment, was often missing.
Conclusions
Overall ribotype prevalence across Europe remained stable
between 2011 and 2016, and a lack of ribotype diversity in
an individual country was associated with greater antimicro-
bial resistance. There was no evidence of reduced susceptibil-
ity to fidaxomicin following its introduction in 2011. The
identification of emerging and highly antimicrobial-resistant
C. difficile PCR ribotypes highlights the importance of con-
tinued surveillance.
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